Press "Enter" to skip to content

The Sarepta saga continues. . .

Chris Temple 0

Generally, I do not make known to anyone other than paid Members the specific ETF's and stocks I recommend; at least until well after they have first had a chance to act, and usually not even then.  But the ongoing story of Sarepta Therapeutics (Nasdaq-SRPT) is more than an investment one; and it's one I want to share.  . It is a deep human interest story (a personal one, too, as you'll read) and a story of just how harmful inhuman and robotic bureaucracy is when LIVES are at stake.

Click below to read this excerpt from the latest issue:

April 27, 2016 - The Sarepta saga continues. . .

Comments are closed.